• Antiretroviral Therapy
    • Jens Dilling Lundgren
    • Jens Dilling Lundgren: Influence Statistics

      Jens Dilling Lundgren

      Jens Dilling Lundgren

      Show email address

      Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark;, neval.ete.wareham@regionh.dk, (N.E.W.);, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Jens Dilling Lundgren:Expert Impact

      Concepts for whichJens Dilling Lundgrenhas direct influence:Antiretroviral therapy,Hiv infection,Viral load,Eastern europe,Cardiovascular disease,Myocardial infarction,Eurosida study,Virological failure.

      Jens Dilling Lundgren:KOL impact

      Concepts related to the work of other authors for whichfor which Jens Dilling Lundgren has influence:Antiretroviral therapy,Hiv infection,Human immunodeficiency virus,Viral load,Infected patients,Cardiovascular disease,South africa.

      KOL Resume for Jens Dilling Lundgren


      Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark;, (N.E.W.);, (A.M.);, (J.L.);, (J.R.)

      CHIP, Department of Infectious Diseases, Copenhagen, Denmark


      CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.

      Rigshospitalet, University of Copenhagen, Copenhagen, Denmark


      Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases 8632, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark


      Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Denmark; Centre for Health, Immunity and Infectious Diseases (CHIP), Rigshospitalet, Copenhagen University Hospital, Denmark.

      Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

      University of Copenhagen - Centre of Excellence for Health, Immunity and Infections CHIP

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Jens Dilling Lundgren is among the top experts in the world.
      Concept World rank
      temporal incidence rate #1
      death recorded underlying #1
      anal cancer nadc #1
      specific antiretrovirals #1
      hsct death #1
      hiv prolonged qtc #1
      maxcmin1 trial #1
      plwh controls #1
      cockcroft−gault #1
      prophylaxis adjusted irr #1
      rtv arm #1
      tbb balf #1
      neutrophil protenase enzymes #1
      influenza immunoglobulin #1
      conductive airway damage #1
      incidence sot groups #1
      failing combination #1
      tuberculosis treatment efavirenz #1
      virological suppression art #1
      drugs antiretroviral therapy #1
      endless watch #1
      illness aids #1
      hcc liver events #1
      hiv indicator #1
      prior kidney function #1
      gcsf infection #1
      serum levels piiinp #1
      clinical society #1
      hivpositive patients europe #1
      eptb pulmonary tuberculosis #1
      tladr risk factors #1
      recurrence clinical cure #1
      antimicrobials thrombocytopenia #1
      910 iu 95 #1
      pcp neutrophil chemotaxis #1
      airr cessation #1
      uptake daa therapy #1
      coinfected participants followup #1
      adcs hiv #1
      match cmv infection #1
      drug resistance europe #1
      incidence primary pcp #1
      people irms #1
      discontinuation tladr #1
      seroconversion decline #1
      haart eurosida cohort #1
      conc ralvs #1
      bal neutrophilia pa #1
      vancouver consensus #1
      gp95 fungal antigens #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Jens Dilling Lundgren

      KOL-Index: 22398

      BACKGROUND: New WHO guidelines recommend initiation of antiretroviral therapy for HIV-positive adults with CD4 counts of 500 cells per μL or less, a higher threshold than was previously recommended. Country decision makers have to decide whether to further expand eligibility for antiretroviral therapy accordingly. We aimed to assess the potential health benefits, costs, and cost-effectiveness of various eligibility criteria for adult antiretroviral therapy and expanded treatment ...

      Known for Antiretroviral Therapy | Cost Daly | 500 Cells | Treatment Coverage | Cd4 Counts
      KOL-Index: 19066

      BACKGROUND: Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.

      METHODS: The Opportunistic ...

      Known for Cd4 Cell | Prophylaxis Patients | Hiv Infection | Incidence Pcp | Primary Pneumocystis
      KOL-Index: 18744

      IMPORTANCE: A key factor in assessing the effectiveness and cost-effectiveness of antiretroviral therapy (ART) as a prevention strategy is the absolute risk of HIV transmission through condomless sex with suppressed HIV-1 RNA viral load for both anal and vaginal sex.

      OBJECTIVE: To evaluate the rate of within-couple HIV transmission (heterosexual and men who have sex with men [MSM]) during periods of sex without condoms and when the HIV-positive partner had HIV-1 RNA load less than 200 ...

      Known for Condomless Sex | Hiv Transmission | Positive Partner | Condoms Risk | Couple Years
      KOL-Index: 17353

      BACKGROUND: Management of tuberculosis in patients with HIV in eastern Europe is complicated by the high prevalence of multidrug-resistant tuberculosis, low rates of drug susceptibility testing, and poor access to antiretroviral therapy (ART). We report 1 year mortality estimates from a multiregional (eastern Europe, western Europe, and Latin America) prospective cohort study: the TB:HIV study.

      METHODS: Consecutive HIV-positive patients aged 16 years or older with a diagnosis of ...

      Known for Latin America | Eastern Europe | Tuberculosis Patients | 12 Months | People Living
      KOL-Index: 16724

      BACKGROUND: The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships.

      METHODS: The PARTNER study was a prospective ...

      Known for Condomless Sex | Hiv Transmission | Antiretroviral Therapy | Partner Study | Viral Load
      KOL-Index: 15919

      BACKGROUND: Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial topic, especially in patients with initially normal renal function. In this study, we aimed to investigate the association between duration of exposure to antiretrovirals and the development of chronic kidney disease in people with initially normal renal function, as measured by estimated glomerular filtration rate (eGFR).

      METHODS: In ...

      Known for Chronic Kidney Disease | Filtration Rate | Estimated Glomerular | Normal Baseline | Positive Individuals
      KOL-Index: 15706

      CONTEXT: It is unclear whether delay in initiation of antiretroviral therapy (ART) may lead to a poorer viral load response for patients with human immunodeficiency virus (HIV).

      OBJECTIVE: To characterize the relationship of viral load response to ART with baseline CD4 cell count and baseline viral load.

      DESIGN: Inception cohort of 3430 therapy-naive patients with HIV, of whom 3226 patients had at least 1 viral load count after the start of ART.

      SETTING: Three cohort studies of patients ...

      Known for Viral Load | Cd4 Cell | 500 Copies | Patients Art | Therapy Baseline
      KOL-Index: 15624

      BACKGROUND: Immediate initiation of antiretroviral therapy (ART) in asymptomatic adults with CD4 counts higher than 500 cells per μL, as recommended, might not always be possible in resource-limited settings. We aimed to identify subgroups of individuals who would benefit most from immediate treatment.

      METHODS: The START trial was a randomised controlled trial in asymptomatic, HIV-positive adults previously untreated with ART. Participants with CD4 counts higher than 500 cells per μL ...

      Known for Antiretroviral Therapy | Start Trial | Art Cd4 | Cd8 Ratio | 500 Cells
      KOL-Index: 15574

      BACKGROUND: In the Strategies for Management of Anti-Retroviral Therapy trial, all-cause mortality was higher for participants randomized to intermittent, CD4-guided antiretroviral treatment (ART) (drug conservation [DC]) than continuous ART (viral suppression [VS]).We hypothesized that increased HIV-RNA levels following ART interruption induced activation of tissue factor pathways, thrombosis, and fibrinolysis.

      METHODS AND FINDINGS: Stored samples were used to measure six biomarkers: ...

      Known for Coagulation Biomarkers | Study Entry | Allcause Mortality | Il6 Ddimer | Latest Levels
      KOL-Index: 15187

      BACKGROUND: Patients with human immunodeficiency virus (HIV) infection and a history of Pneumocystis carinii pneumonia are at high risk for relapse if they are not given secondary prophylaxis. Whether secondary prophylaxis against P. carinii pneumonia can be safely discontinued in patients who have a response to highly active antiretroviral therapy is not known.

      METHODS: We analyzed episodes of recurrent P. carinii pneumonia in 325 HIV-infected patients (275 men and 50 women) in eight ...

      Known for Secondary Prophylaxis | Hiv Infection | Cubic Millimeter | Pneumocystis Carinii | Antiretroviral Therapy Patients
      KOL-Index: 14992

      BACKGROUND: Combination antiretroviral therapy (cART) has been shown to reduce mortality and morbidity in patients with HIV. As viral replication falls, the CD4 count increases, but whether the CD4 count returns to the level seen in HIV-negative people is unknown. We aimed to assess whether the CD4 count for patients with maximum virological suppression (viral load <50 copies per mL) continues to increase with long-term cART to reach levels seen in HIV-negative populations.

      METHODS: We ...

      Known for Cd4 Count | Cart Patients | 5 Years | Observational Cohort Study | Combination Antiretroviral
      KOL-Index: 14687

      BACKGROUND: Although earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted darunavir were associated with increased incidence of cardiovascular disease in people living with HIV.

      METHODS: The prospective Data Collection on Adverse Events of Anti-HIV Drugs ...

      Known for Cardiovascular Disease | Protease Inhibitors | 1000 Personyears | Darunavir Ritonavir | People Hiv
      KOL-Index: 14351

      OBJECTIVES: To analyse use of antiretroviral therapy within Europe between 1994 and 1997.

      DESIGN: From September 1994, the EuroSIDA study (cohorts I-III) has prospectively followed unselected HIV-infected patients from 50 clinical centres in 17 European countries (total, 7230).

      METHODS: Patients under follow-up at half-year intervals from September 1994 (n=2871) to September 1997 (n=3682) were classified according to number of drugs currently used (none, one, two, three, four or more). ...

      Known for Antiretroviral Therapy | Regions Europe | Patients September | Time Proportion | Protease Inhibitors

      Key People For Antiretroviral Therapy

      Top KOLs in the world
      Andrew N Phillips†
      antiretroviral therapy viral load hiv infection
      Jens Dilling Lundgren
      antiretroviral therapy hiv infection viral load
      Peter Reiss†
      antiretroviral therapy hiv infection myocardial infarction
      David A Cooper
      antiretroviral therapy hiv infection viral load
      Joseph J Eron
      antiretroviral therapy united states hiv infection
      Douglas D Richman†
      antiretroviral therapy hiv infection human immunodeficiency virus

      Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark;, neval.ete.wareham@regionh.dk, (N.E.W.);, amanda.mocroft@regionh.dk, (A.M.);, jens.lundgren@regionh.dk, (J.L.);, joan

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.